The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis

Brent Kelly, Leslie Scroggins Markle, Jennifer L. Vickers, Matthew S. Petitt, Sharon Raimer, Catherine McNeese

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Nephrogenic systemic fibrosis (NSF) occurs in patients with renal dysfunction and gadolinium exposure. Although little is known about the pathogenesis of this disease, increased expression of transforming growth factor-β has been recently demonstrated. Other fibrosing conditions have been shown to express an imbalance in matrix metalloproteinase (MMP) expression and their corresponding inhibitors. Myofibroblast differentiation, in which cells often express α-smooth muscle actin and achieve the ability to contract, is also a hallmark of fibrosis. Objective: We theorized that NSF may overexpress tissue inhibitor of metalloproteinase-1 (TIMP-1), while simultaneously showing decreased expression of MMP-1. As a secondary aim, we sought to evaluate the presence of smooth muscle actin in our samples. Methods: We applied immunohistochemistry to 16 skin biopsies from 10 patients with NSF using antibodies to TIMP-1, MMP-1, MMP-2, MMP-9, and α-smooth muscle actin. Samples from normal skin, scar, keloid and scleroderma were stained for comparison. Results: TIMP-1 was strongly expressed in all NSF specimens compared to normal skin. MMP-1 expression was nearly absent in all tested samples. In all 16 NSF cases, the dermal spindle cells did not stain for α-smooth muscle actin. MMP-2 and MMP-9 expression was variable but was increased compared to normal skin. Limitations: The expression is semiquantitative and based on immunohistochemistry and unconfirmed by other techniques. Conclusions: In NSF, TIMP-1 is strongly expressed and MMP-1 is nearly absent, characteristic of the MMP imbalances seen in other fibrosing processes. Using smooth muscle actin immunohistochemistry, there was no evidence of myofibroblast differentiation.

Original languageEnglish (US)
Pages (from-to)483-489
Number of pages7
JournalJournal of the American Academy of Dermatology
Volume63
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

Nephrogenic Fibrosing Dermopathy
Matrix Metalloproteinases
Matrix Metalloproteinase 1
Tissue Inhibitor of Metalloproteinase-1
Smooth Muscle
Actins
Skin
Myofibroblasts
Immunohistochemistry
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Keloid
Gadolinium
Transforming Growth Factors
Cicatrix
Fibrosis
Coloring Agents
Kidney
Biopsy
Antibodies

Keywords

  • Matrix metalloproteinase
  • Myofibroblast
  • Nephrogenic fibrosing dermopathy
  • Nephrogenic systemic fibrosis
  • Smooth muscle actin
  • Tissue inhibitor of matrix metalloproteinase
  • Transforming growth factor

ASJC Scopus subject areas

  • Dermatology
  • Medicine(all)

Cite this

The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis. / Kelly, Brent; Markle, Leslie Scroggins; Vickers, Jennifer L.; Petitt, Matthew S.; Raimer, Sharon; McNeese, Catherine.

In: Journal of the American Academy of Dermatology, Vol. 63, No. 3, 09.2010, p. 483-489.

Research output: Contribution to journalArticle

Kelly, Brent ; Markle, Leslie Scroggins ; Vickers, Jennifer L. ; Petitt, Matthew S. ; Raimer, Sharon ; McNeese, Catherine. / The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis. In: Journal of the American Academy of Dermatology. 2010 ; Vol. 63, No. 3. pp. 483-489.
@article{0bb118f6d8ed482995b90f782e3cfcc2,
title = "The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis",
abstract = "Background: Nephrogenic systemic fibrosis (NSF) occurs in patients with renal dysfunction and gadolinium exposure. Although little is known about the pathogenesis of this disease, increased expression of transforming growth factor-β has been recently demonstrated. Other fibrosing conditions have been shown to express an imbalance in matrix metalloproteinase (MMP) expression and their corresponding inhibitors. Myofibroblast differentiation, in which cells often express α-smooth muscle actin and achieve the ability to contract, is also a hallmark of fibrosis. Objective: We theorized that NSF may overexpress tissue inhibitor of metalloproteinase-1 (TIMP-1), while simultaneously showing decreased expression of MMP-1. As a secondary aim, we sought to evaluate the presence of smooth muscle actin in our samples. Methods: We applied immunohistochemistry to 16 skin biopsies from 10 patients with NSF using antibodies to TIMP-1, MMP-1, MMP-2, MMP-9, and α-smooth muscle actin. Samples from normal skin, scar, keloid and scleroderma were stained for comparison. Results: TIMP-1 was strongly expressed in all NSF specimens compared to normal skin. MMP-1 expression was nearly absent in all tested samples. In all 16 NSF cases, the dermal spindle cells did not stain for α-smooth muscle actin. MMP-2 and MMP-9 expression was variable but was increased compared to normal skin. Limitations: The expression is semiquantitative and based on immunohistochemistry and unconfirmed by other techniques. Conclusions: In NSF, TIMP-1 is strongly expressed and MMP-1 is nearly absent, characteristic of the MMP imbalances seen in other fibrosing processes. Using smooth muscle actin immunohistochemistry, there was no evidence of myofibroblast differentiation.",
keywords = "Matrix metalloproteinase, Myofibroblast, Nephrogenic fibrosing dermopathy, Nephrogenic systemic fibrosis, Smooth muscle actin, Tissue inhibitor of matrix metalloproteinase, Transforming growth factor",
author = "Brent Kelly and Markle, {Leslie Scroggins} and Vickers, {Jennifer L.} and Petitt, {Matthew S.} and Sharon Raimer and Catherine McNeese",
year = "2010",
month = "9",
doi = "10.1016/j.jaad.2009.09.006",
language = "English (US)",
volume = "63",
pages = "483--489",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis

AU - Kelly, Brent

AU - Markle, Leslie Scroggins

AU - Vickers, Jennifer L.

AU - Petitt, Matthew S.

AU - Raimer, Sharon

AU - McNeese, Catherine

PY - 2010/9

Y1 - 2010/9

N2 - Background: Nephrogenic systemic fibrosis (NSF) occurs in patients with renal dysfunction and gadolinium exposure. Although little is known about the pathogenesis of this disease, increased expression of transforming growth factor-β has been recently demonstrated. Other fibrosing conditions have been shown to express an imbalance in matrix metalloproteinase (MMP) expression and their corresponding inhibitors. Myofibroblast differentiation, in which cells often express α-smooth muscle actin and achieve the ability to contract, is also a hallmark of fibrosis. Objective: We theorized that NSF may overexpress tissue inhibitor of metalloproteinase-1 (TIMP-1), while simultaneously showing decreased expression of MMP-1. As a secondary aim, we sought to evaluate the presence of smooth muscle actin in our samples. Methods: We applied immunohistochemistry to 16 skin biopsies from 10 patients with NSF using antibodies to TIMP-1, MMP-1, MMP-2, MMP-9, and α-smooth muscle actin. Samples from normal skin, scar, keloid and scleroderma were stained for comparison. Results: TIMP-1 was strongly expressed in all NSF specimens compared to normal skin. MMP-1 expression was nearly absent in all tested samples. In all 16 NSF cases, the dermal spindle cells did not stain for α-smooth muscle actin. MMP-2 and MMP-9 expression was variable but was increased compared to normal skin. Limitations: The expression is semiquantitative and based on immunohistochemistry and unconfirmed by other techniques. Conclusions: In NSF, TIMP-1 is strongly expressed and MMP-1 is nearly absent, characteristic of the MMP imbalances seen in other fibrosing processes. Using smooth muscle actin immunohistochemistry, there was no evidence of myofibroblast differentiation.

AB - Background: Nephrogenic systemic fibrosis (NSF) occurs in patients with renal dysfunction and gadolinium exposure. Although little is known about the pathogenesis of this disease, increased expression of transforming growth factor-β has been recently demonstrated. Other fibrosing conditions have been shown to express an imbalance in matrix metalloproteinase (MMP) expression and their corresponding inhibitors. Myofibroblast differentiation, in which cells often express α-smooth muscle actin and achieve the ability to contract, is also a hallmark of fibrosis. Objective: We theorized that NSF may overexpress tissue inhibitor of metalloproteinase-1 (TIMP-1), while simultaneously showing decreased expression of MMP-1. As a secondary aim, we sought to evaluate the presence of smooth muscle actin in our samples. Methods: We applied immunohistochemistry to 16 skin biopsies from 10 patients with NSF using antibodies to TIMP-1, MMP-1, MMP-2, MMP-9, and α-smooth muscle actin. Samples from normal skin, scar, keloid and scleroderma were stained for comparison. Results: TIMP-1 was strongly expressed in all NSF specimens compared to normal skin. MMP-1 expression was nearly absent in all tested samples. In all 16 NSF cases, the dermal spindle cells did not stain for α-smooth muscle actin. MMP-2 and MMP-9 expression was variable but was increased compared to normal skin. Limitations: The expression is semiquantitative and based on immunohistochemistry and unconfirmed by other techniques. Conclusions: In NSF, TIMP-1 is strongly expressed and MMP-1 is nearly absent, characteristic of the MMP imbalances seen in other fibrosing processes. Using smooth muscle actin immunohistochemistry, there was no evidence of myofibroblast differentiation.

KW - Matrix metalloproteinase

KW - Myofibroblast

KW - Nephrogenic fibrosing dermopathy

KW - Nephrogenic systemic fibrosis

KW - Smooth muscle actin

KW - Tissue inhibitor of matrix metalloproteinase

KW - Transforming growth factor

UR - http://www.scopus.com/inward/record.url?scp=77955864516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955864516&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2009.09.006

DO - 10.1016/j.jaad.2009.09.006

M3 - Article

C2 - 20708474

AN - SCOPUS:77955864516

VL - 63

SP - 483

EP - 489

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 3

ER -